0000000000022185

AUTHOR

Michael H. Davidson

showing 4 related works from this author

An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia.

2014

An international panel of the International Atherosclerosis Society has developed a new set of recommendations for management of dyslipidemia. The panel identifies non-high density lipoprotein cholesterol (non-HDL-C) as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for higher risk subjects. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or r…

Gerontologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismAlternative medicineMEDLINEPharmacologychemistry.chemical_compoundPharmacotherapyRisk FactorsEnvironmental healthInternal MedicinemedicineHumansSocieties MedicalDyslipidemiasMetabolic SyndromeNutrition and DieteticsExecutive summaryCholesterolLife stylebusiness.industryAnticholesteremic AgentsCholesterol LDLmedicine.diseaseDietchemistryCardiovascular DiseasesPosition paperlipids (amino acids peptides and proteins)Lifetime riskPopulation RiskMetabolic syndromeRisk assessmentCardiology and Cardiovascular MedicinebusinessDyslipidemiaJournal of clinical lipidology
researchProduct

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term ‘statin intolerance’. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 – 15% of patients.In clinical practice, statin intolerance limits effectiv…

medicine.medical_specialtyStatinmedicine.drug_classbusiness.industrynutritional and metabolic diseasesGeneral MedicineDisease3. Good healthClinical PracticemedicineEuropean atherosclerosis societyPhysical therapyEffective treatmentPosition paperlipids (amino acids peptides and proteins)Pharmacology (medical)cardiovascular diseasesStatin therapyIntensive care medicinebusinessAdverse effectExpert Opinion on Drug Safety
researchProduct

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients. In clinical practice, statin intolerance limits effective…

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classAlternative medicinePlacebo-controlled studynutritional and metabolic diseasesGeneral MedicineDiseasecomputer.software_genre3. Good healthlaw.inventionRandomized controlled triallawPost-hoc analysismedicinePosition paperlipids (amino acids peptides and proteins)cardiovascular diseasesData miningbusinessIntensive care medicineAdverse effectcomputerArchives of Medical Science
researchProduct